Cargando…
Targeting omicron and other reported SARS-CoV-2 lineages by potent inhibitors of main protease 3CL Mpro: Molecular simulation analysis
Autores principales: | Saeed, Aamir, Ahmad, Basharat, Majaz, Sidra, Nouroz, Faisal, Ahmad, Ashfaq, Xie, Yingqiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851874/ https://www.ncbi.nlm.nih.gov/pubmed/35183608 http://dx.doi.org/10.1016/j.jinf.2022.02.012 |
Ejemplares similares
-
Targeting severe symptoms of early 2023-new outbreak of COVID-19 by classical drug dexamethasone: a potential fatality reducing agent
por: Liu, Dongsheng, et al.
Publicado: (2023) -
Omicron N501Y mutation among SARS-CoV-2 lineages: In silico analysis of potent binding to tyrosine kinase and hypothetical repurposed medicine
por: Kazybay, Bexultan, et al.
Publicado: (2022) -
Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
por: Pavan, Matteo, et al.
Publicado: (2022) -
Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences
por: Narkhede, Rohan R., et al.
Publicado: (2020) -
Molecular modeling and simulations of some antiviral drugs, benzylisoquinoline alkaloid, and coumarin molecules to investigate the effects on Mpro main viral protease inhibition
por: Mir, Showkat Ahmad, et al.
Publicado: (2023)